International regulatory harmonisation meeting in the US
This article was originally published in Clinica
The regulatory conference Creating a globally harmonized quality system will take place during March 9-11 2009 at the Westin Hotel in Las Vegas. The event’s focus is best practices for creating and auditing a globally harmonised quality system and will be of special interest to those who sell devices or IVDs in multiple international markets. Senior- level speakers at the event will be Evangeline Loh, Jaap Laufer and Julie Powell of the Emergo Group regulatory consultancy. Other speakers will hail from the US FDA and industry leading companies such as Boston Scientific, Guidant and Hitachi. Some of the topics to be covered, are: challenges in complying with the FDA quality system regulation; lessons learned in synchronising a quality system that complies with US and Japanese requirements; FDA's expectations for device firms with international facilities; and an exercise on challenges of working with notified bodies. For further information and to register, go to: www.compliance-alliance.com/dv09lv.htm
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.